PRESS RELEASE
News
-
-
PRESS RELEASE
Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented -
-
-
-
-
-
-
PRESS RELEASE
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Inventiva announces publication in Biomedicine & Pharmacotherapy of preclinical study results indicating lanifibranor's effectiveness in improving portal hypertension, potentially addressing complications of chronic liver diseases -
PRESS RELEASE
Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor
Inventiva annonce des résultats prometteurs d'une étude préclinique sur lanifibranor pour traiter l'hypertension portale, publiés dans Biomedicine & Pharmacotherapy
